Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy
Journal of the American Heart Association · 17.03.2026 · 15 (6)
DOI: 10.1161/jaha.125.041231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 17.03.2026. Verfasst von Anjali T Owens und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Septal Myectomy, Health Services Accessibility, Heart Septum. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
In symptomatic patients with treatment‐refractory obstructive hypertrophic cardiomyopathy, septal reduction therapy (SRT) is recommended to relieve obstruction. This study examined the challenges associated with SRT access in the United States.
Methods
Cross‐sectional study of commercially insured individuals or Medicare Advantage with Part D members captured in the Optum Research Database from May 2012 to April 2022. Patients with obstructive hypertrophic cardiomyopathy who underwent SRT were identified based on diagnosis/procedure codes. Treatment center procedural volume was defined based on tertiles. SRT access was assessed by the distance patients traveled to care and the proportion of patients treated at hypertrophic cardiomyopathy centers of excellence (COE) by region. Cohorts of patients with coronary artery disease who underwent percutaneous coronary intervention or coronary artery bypass grafting were compared with the SRT cohort.
Results
Overall, 1864 patients who underwent SRT, 235 652 with percutaneous coronary intervention, and 69 236 with coronary artery bypass grafting were included. In the SRT cohort, 368 patients (19.7%) underwent procedures at COE. A greater proportion of patients who traveled long distances for care (≥50 miles) underwent SRT at COE (35.7%) or high‐volume facilities (43.8%) than those who traveled short distances (0–
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA.
- Bristol Myers Squibb Princeton NJ USA.
- Optum Eden Prairie MN USA.
ORCID-Profile: Anjali T Owens, Patricia Schuler, Jenny Jiang, Ervant Maksabedian Hernandez, Andrea Steffens, Anandkumar Dubey
Zitieren
APA
Owens, A. T., Schuler, P., Jiang, J., Han, X., Hernandez, E. M., Anderson, A., Fang, Y., Steffens, A., & Dubey, A. (2026). Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 15(6). https://doi.org/10.1161/jaha.125.041231
Vancouver
Owens AT, Schuler P, Jiang J, Han X, Hernandez EM, Anderson A, et al. Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 2026;15(6). doi:10.1161/jaha.125.041231
BibTeX
@article{Owens2026,
author = {Owens, Anjali T and Schuler, Patricia and Jiang, Jenny and Han, Xu and Hernandez, Ervant Maksabedian and Anderson, Amy and Fang, Yiyu and Steffens, Andrea and Dubey, Anandkumar},
title = {Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {6},
doi = {10.1161/jaha.125.041231}
}
EUVIMED